Read more

December 11, 2020
1 min read
Save

Top in GI: Optical diagnosis of colorectal polyps, Stelara and perianal Crohn’s

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers reported that Optivista image-enhancing endoscopy should be the preferred modality for optical diagnosis of colorectal polyps. It was the top story in gastroenterology last week.

Another top story was about a study that showed Stelara (ustekinumab, Janssen) may be an effective therapeutic treatment for perianal Crohn’s disease.

Research files Adobe
Source: Adobe Stock

Read these and more top stories in gastroenterology below:

Opivista image-enhancing endoscopy superior for diagnosis of colorectal polyps

Optical diagnosis of colorectal polyps with Optivista (Pentax) image-enhancing endoscopy was superior to iScan image-enhancing endoscopy, according to study results published in Gastrointestinal Endoscopy. Read more.

Stelara may be effective therapeutic for perianal Crohn’s

Ustekinumab may be an effective therapeutic treatment in perianal refractory Crohn’s disease, data show. Read more.

VIDEO: Atopy allergy patch tests link with improvements in EoE

In this exclusive video, Gaurav Ghosh, MD, from Weill Cornell Medical Center in New York, discussed the use of comprehensive atopy allergy patch tests in identifying eosinophilic esophagitis hypersensitivity triggers. Read more.

Changes in duodenal fluid microbiome profile seen in pancreatic cancer

Patients with pancreas ductal adenocarcinoma, compared with pancreatic cysts or normal pancreata, had changes in their duodenal fluid microbiome profiles, according to study results. Read more.

Abivax completes enrollment for study of ulcerative colitis candidate

Abivax has completed enrollment of a phase 2b induction study for its ulcerative colitis drug candidate ABX464, according to a company press release. Read more.